ADC Therapeutics (ADCT) announced Loss for fourth quarter of -$30.73 million
The company's bottom line totaled -$30.73 million, or -$0.29 per share. This compares with -$85.03 million, or -$1.03 per share, last year.
Excluding items, ADC Therapeutics reported adjusted earnings of -$26.48 million or -$0.25 per share for the period.
The company's revenue for the period rose 0.7% to $16.91 million from $16.79 million last year.
ADC Therapeutics earnings at a glance (GAAP) :
-Earnings: -$30.73 Mln. vs. -$85.03 Mln. last year.
-EPS: -$0.29 vs. -$1.03 last year.
-Revenue: $16.91 Mln vs. $16.79 Mln last year.
For comments and feedback: editorial@rttnews.com